WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

Cassandra Rayer  1     Xavier Roblin  2     David Laharie  3     Mathurin Flamant  4     Marie Dewitte  4     Mathurin Fumery  5     Bénédicte Caron  6     Stéphanie Viennot  7     Benjamin Pariente  8     Laurent Siproudhis  8     Laurent Peyrin-Biroulet  9     Guillaume Bouguen  9    
1 CHU Pontchaillou, Rennes, France
2 University of St. Etienne Dept. de Gastroenterologie, Saint Etienne, France
3 CHU de Bordeaux Hopital Haut-Leveque, Pessac, France
4 Clinique Jules Verne, Nantes, France
5 Amiens University Hospital, Amiens, France
6 Hopital de Hautepierre, Strasbourg, France
7 CHRU de Caen HGE, Caen, France
8 Saint-Louis Hospital International Program to Develop New Indexes, Lille, France
9 Nancy University Hospital Inserm U954 Dept. of Hepato-Gastroenterology, Vandoeuvre les Nancy, France

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing